Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcγRIIIA

Biochemical and Biophysical Research Communications

Volumn 436, Issue 3, 2013, Pages 519-524

  Suzuki, Mami ^a   Yamanoi, Ayaka ^a   Machino, Yusuke ^a   Kobayashi, Eiji ^a,b   Fukuchi, Kaori ^a   Tsukimoto, Mitsutoshi ^a   Kojima, Shuji ^a   Kohroki, Junya ^a,c   Akimoto, Kazunori ^a   Masuho, Yasuhiko ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

ADCC; Effector function; Fc RIIIA; Granzyme B; Interchain disulfide bond; Rituximab

Indexed keywords

FC RECEPTOR IIIA; GRANZYME B; IMMUNOGLOBULIN RECEPTOR; PERFORIN; RITUXIMAB; UNCLASSIFIED DRUG;

ALKYLATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; EFFECTOR CELL; ENZYME RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RECEPTOR AFFINITY; SULFONATION;

A-RTX; ADCC; ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; EFFECTOR FUNCTION; FCΓ RECEPTOR; FCΓR; FCΓRIIIA; GRANZYME B; INTERCHAIN DISULFIDE BOND; KHYG-1 CELLS STABLY EXPRESSING FCΓRIIIA; KHYG-1/FCΓRIIIA; MAB; MONOCLONAL ANTIBODY; REDUCED AND THEN ALKYLATED RITUXIMAB; RITUXIMAB; RTX; S-RTX; S-SULFONATED RITUXIMAB; SDS-PAGE; SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS;

ALKYLATION; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISULFIDES; GRANZYMES; HUMANS; KILLER CELLS, NATURAL; PERFORIN; PROTEIN BINDING; PROTEOLYSIS; RECEPTORS, IGG;

EID: 84879887781     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.05.137     Document Type: Article

References (20)

1. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
2. Brekke O.H., Michaelsen T.E., Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge?. Immunol. Today 1995, 16:85-90.
3. Nimmerjahn F., Ravetch J.V. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 2007, 19:239-245.
4. Takai T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2002, 2:580-592.
5. Sondermann P., Huber R., Oosthuizen V., Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 2000, 406:267-273.
6. Masuho Y., Tomibe K., Matsuzawa K., Ohtsu A. Development of an intravenous g-globulin with Fc activities: I. Preparation and characterization of S-sulfonated human g-globulin. Vox Sang. 1977, 32:175-181.
7. Liu H., Chumsae C., Gaza-Bulseco G., Hurkmans K., Radziejewski C.H. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal. Chem. 2010, 82:5219-5226.
8. Michaelsen T.E. Alteration of the conformation of human IgG subclasses by reduction of the hinge S-S bonds. Mol. Immunol. 1988, 25:639-646.
9. Dall'Acqua W.F., Cook K.E., Damschroder M.M., Woods R.M., Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 2006, 177:1129-1138.
10. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xiei D., Lai J., Stadlen A., Li B., Foxi J.A., Presta L.G. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 2001, 276:65910-66601.
11. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278:3466-3473.
12. Maloney D.G. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 2012, 366:2008-2016.
13. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002, 99:754-758.
14. Machino Y., Ohta H., Suzuki E., Higurashi S., Tezuka T., Nagashima H., Kohroki J., Masuho Y. Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP). Clin. Exp. Immunol. 2010, 162:415-424.
15. Nagashima H., Tezuka T., Tsuchida W., Maeda H., Kohroki J., Masuho Y. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity. Mol. Immunol. 2008, 45:2752-2763.
16. Cheent K., Khakoo S.I. Natural killer cells: integrating diversity with function. Immunology 2009, 126:449-457.
17. Wishart D.S., Knox C., Guo A.C., Cheng D., Shrivastava S., Tzur D., Gautam B., Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36:D901-D906.
18. Yagita M., Huang C.L., Umehara H., Matsuo Y., Tabata R., Miyake M., Konaka Y., Takatsuki K. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000, 14:922-930.
19. Suck G., Branch D.R., Smyth M.J., Miller R.G., Vergidis J., Fahim S., Keating A. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp. Hematol. 2005, 33:1160-1171.
20. Kruspe A.S., Katsman Y., Sakac D., Chagneau C., Glistvain A., Langler R.F., Branch D.R. Reduction of disulfide bonds within anti-D results in enhanced Fcgamma receptor blockade. Transfusion 2009, 49:928-936.